David Arkowitz - Net Worth and Insider Trading

David Arkowitz Net Worth

The estimated net worth of David Arkowitz is at least $2 Million dollars as of 2026-07-12. David Arkowitz is the CFO of Flexion Therapeutics Inc and owns about 220,719 shares of Flexion Therapeutics Inc (FLXN) stock worth over $2 Million. David Arkowitz is the CFO of Seres Therapeutics Inc and owns about 9,122 shares of Seres Therapeutics Inc (MCRB) stock worth over $55,735. David Arkowitz is also the Director of iBio Inc and owns about 18,382 shares of iBio Inc (IBIO) stock worth over $27,757. Besides these, David Arkowitz also holds AMAG Pharmaceuticals Inc (AMAG) , Spring Bank Pharmaceuticals Inc (SBPH) . Details can be seen in David Arkowitz's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that David Arkowitz has not made any transactions after 2025-01-10 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of David Arkowitz

Are these stocks worth buying? — GuruFocus analysis for each holding

- GF

FLXN Flexion Therapeutics Inc

94% of holdings · $2.0M

MCRB Seres Therapeutics Inc

3% of holdings · $56K

SBPH Spring Bank Pharmaceuticals Inc

1% of holdings · $23K

1% of holdings · $28K

AMAG AMAG Pharmaceuticals Inc

1% of holdings · $25K

David Arkowitz Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, David Arkowitz owns 9 companies in total, including Flexion Therapeutics Inc (FLXN) , Proteostasis Therapeutics Inc (PTI) , and Spring Bank Pharmaceuticals Inc (SBPH) among others .

Click here to see the complete history of David Arkowitz’s form 4 insider trades.

Insider Ownership Summary of David Arkowitz

Ticker	Company	Transaction Date	Type of Owner
FLXN	Flexion Therapeutics Inc	2021-05-10	Chief Financial Officer
PTI	Proteostasis Therapeutics Inc	2020-06-29	director
SBPH	Spring Bank Pharmaceuticals Inc	2020-06-24	director
		2011-05-31	EVP & CFO and CBO
		2020-12-22	director
		2016-05-05	director
		2024-02-16	Chief Financial Officer
		2020-12-22	director
		2024-11-21	director

David Arkowitz Latest Holdings Summary

David Arkowitz currently owns a total of 5 stocks. Among these stocks, David Arkowitz owns 220,719 shares of Flexion Therapeutics Inc (FLXN) as of May 10, 2021, with a value of $2 Million and a weighting of 93.86%. David Arkowitz owns 9,122 shares of Seres Therapeutics Inc (MCRB) as of February 16, 2024, with a value of $55,735 and a weighting of 2.6%. David Arkowitz also owns 18,382 shares of iBio Inc (IBIO) as of January 10, 2025, with a value of $27,757 and a weighting of 1.29%. The other 2 stocks AMAG Pharmaceuticals Inc (AMAG) , Spring Bank Pharmaceuticals Inc (SBPH) have a combined weighting of 2.25% among all his current holdings.

Latest Holdings of David Arkowitz

Ticker	Company	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
FLXN	Flexion Therapeutics Inc	2021-05-10	220,719	9.12	2,012,957
MCRB	Seres Therapeutics Inc	2024-02-16	9,122	6.11	55,735
IBIO	iBio Inc	2025-01-10	18,382	1.51	27,757
AMAG	AMAG Pharmaceuticals Inc	2011-05-31	1,806	13.75	24,833
SBPH	Spring Bank Pharmaceuticals Inc	2017-08-04	4,846	4.84	23,455

Holding Weightings of David Arkowitz

David Arkowitz Form 4 Trading Tracker

According to the SEC Form 4 filings, David Arkowitz has made a total of 0 transactions in Flexion Therapeutics Inc (FLXN) over the past 5 years. The most-recent trade in Flexion Therapeutics Inc is the sale of 2,229 shares on May 10, 2021, which brought David Arkowitz around $16,116.

According to the SEC Form 4 filings, David Arkowitz has made a total of 2 transactions in Seres Therapeutics Inc (MCRB) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Seres Therapeutics Inc is the sale of 197 shares on February 16, 2024, which brought David Arkowitz around $4,254.

According to the SEC Form 4 filings, David Arkowitz has made a total of 1 transactions in iBio Inc (IBIO) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in iBio Inc is the acquisition of 18,382 shares on January 10, 2025, which cost David Arkowitz around $49,999.

More details on David Arkowitz's insider transactions can be found in the Insider Trading History of David Arkowitz table.

Insider Trading History of David Arkowitz

* The information on this page (including Insider Trading Shares, Share Changes, Cost, etc.) is sourced exclusively from Form 4 filings and does not incorporate any data from 13F or 13D/G filings. As a result, it may differ from the values shown on the Guru page.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

David Arkowitz Trading Performance

GuruFocus tracks the stock performance after each of David Arkowitz's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by David Arkowitz is -11.52%. GuruFocus also compares David Arkowitz's trading performance to market benchmark return within the same time period. The performance of stocks bought by David Arkowitz within 3 months outperforms 3 times out of 12 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how David Arkowitz's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of David Arkowitz

Average Return

Average return per transaction

Outperforming Transactions

4 out of 12 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	3.89
Relative Return to S&P 500(%)	3.65

Get the full picture on these stocks

See GF Score, valuation, financials, and warning signs for every stock David Arkowitz owns.

- FLXN - MCRB - IBIO - AMAG - SBPH

View FLXN Analysis

David Arkowitz Ownership Network

Ownership Network List of David Arkowitz

No Data

Ownership Network Relation of David Arkowitz

David Arkowitz Owned Company Details

What does Flexion Therapeutics Inc do?

Who are the key executives at Flexion Therapeutics Inc?

David Arkowitz is the Chief Financial Officer of Flexion Therapeutics Inc. Other key executives at Flexion Therapeutics Inc include Chief Regulatory Officer Kerry Wentworth , Chief Strategy Officer Christina Willwerth , and General Counsel Mark S. Levine .

Flexion Therapeutics Inc (FLXN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Flexion Therapeutics Inc (FLXN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Flexion Therapeutics Inc (FLXN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Flexion Therapeutics Inc (FLXN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Flexion Therapeutics Inc Insider Transactions

No Available Data

What does Proteostasis Therapeutics Inc do?

Who are the key executives at Proteostasis Therapeutics Inc?

David Arkowitz is the director of Proteostasis Therapeutics Inc. Other key executives at Proteostasis Therapeutics Inc include Interim Head of Finance Michael Alfieri , director & President and CEO Meenu Chhabra , and See Remarks Eric D Larson .

Proteostasis Therapeutics Inc (PTI) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Proteostasis Therapeutics Inc (PTI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Proteostasis Therapeutics Inc (PTI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Proteostasis Therapeutics Inc (PTI)'s detailed insider trading history can be found in Insider Trading Tracker table.

Proteostasis Therapeutics Inc Insider Transactions

No Available Data

What does Spring Bank Pharmaceuticals Inc do?

Who are the key executives at Spring Bank Pharmaceuticals Inc?

David Arkowitz is the director of Spring Bank Pharmaceuticals Inc. Other key executives at Spring Bank Pharmaceuticals Inc include VP of Finance and Treasurer Lori Firmani , director & President and CEO Martin J Driscoll , and Chief Scientific Officer Radhakrishnan P. Iyer .

Spring Bank Pharmaceuticals Inc (SBPH) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Spring Bank Pharmaceuticals Inc (SBPH) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Spring Bank Pharmaceuticals Inc (SBPH) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Spring Bank Pharmaceuticals Inc (SBPH)'s detailed insider trading history can be found in Insider Trading Tracker table.

Spring Bank Pharmaceuticals Inc Insider Transactions

No Available Data

What does AMAG Pharmaceuticals Inc do?

Who are the key executives at AMAG Pharmaceuticals Inc?

David Arkowitz is the EVP & CFO and CBO of AMAG Pharmaceuticals Inc. Other key executives at AMAG Pharmaceuticals Inc include 10 percent owner Camber Capital Management Llc , Chief Operating Officer Anthony Casciano , and Interim CFO Brian Piekos .

AMAG Pharmaceuticals Inc (AMAG) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of AMAG Pharmaceuticals Inc (AMAG) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of AMAG Pharmaceuticals Inc (AMAG) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

AMAG Pharmaceuticals Inc (AMAG)'s detailed insider trading history can be found in Insider Trading Tracker table.

AMAG Pharmaceuticals Inc Insider Transactions

No Available Data

What does Yumanity Therapeutics Inc do?

Who are the key executives at Yumanity Therapeutics Inc?

David Arkowitz is the director of Yumanity Therapeutics Inc. Other key executives at Yumanity Therapeutics Inc include director & Chief Executive Officer Shawn Iadonato , Chief Scientific Officer Thierry Guillaudeux , and Chief Financial Officer Keith Baker .

Yumanity Therapeutics Inc (YMTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Yumanity Therapeutics Inc (YMTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Yumanity Therapeutics Inc (YMTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Yumanity Therapeutics Inc (YMTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Yumanity Therapeutics Inc Insider Transactions

No Available Data

What does F-star Therapeutics Inc do?

Who are the key executives at F-star Therapeutics Inc?

David Arkowitz is the director of F-star Therapeutics Inc. Other key executives at F-star Therapeutics Inc include See Remarks Darlene M Deptula-hicks , CHIEF SCIENTIFIC OFFICER Neil Brewis , and CHIEF MEDICAL OFFICER Louis Kayitalire .

F-star Therapeutics Inc (FSTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of F-star Therapeutics Inc (FSTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of F-star Therapeutics Inc (FSTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

F-star Therapeutics Inc (FSTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

F-star Therapeutics Inc Insider Transactions

No Available Data

What does Seres Therapeutics Inc do?

Who are the key executives at Seres Therapeutics Inc?

David Arkowitz is the Chief Financial Officer of Seres Therapeutics Inc. Other key executives at Seres Therapeutics Inc include See Remarks Kelly Brady , Chief Scientific Officer Matthew R. Henn , and CFO and EVP Eric D. Shaff .

Seres Therapeutics Inc (MCRB) Insider Trades Summary

Over the past 18 months, David Arkowitz made no insider transaction in Seres Therapeutics Inc (MCRB). Other recent insider transactions involving Seres Therapeutics Inc (MCRB) include a net sale of 13,898 shares made by Eric D. Shaff , a net sale of 5,526 shares made by Matthew R. Henn , and a net sale of 4,688 shares made by Thomas Desrosier .

In summary, during the past 3 months, insiders sold 474 shares of Seres Therapeutics Inc (MCRB) in total and bought 0 shares, with a net sale of 474 shares. During the past 18 months, 5,868 shares of Seres Therapeutics Inc (MCRB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 5,868 shares.

Seres Therapeutics Inc (MCRB)'s detailed insider trading history can be found in Insider Trading Tracker table.

Seres Therapeutics Inc Insider Transactions

No Available Data

What does Kineta Inc do?

Who are the key executives at Kineta Inc?

David Arkowitz is the director of Kineta Inc. Other key executives at Kineta Inc include director & Chief Executive Officer Shawn Iadonato , President Craig W. Philips , and General Counsel Pauline Kenny .

Kineta Inc (KANT) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Kineta Inc (KANT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Kineta Inc (KANT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Kineta Inc (KANT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Kineta Inc Insider Transactions

No Available Data

What does iBio Inc do?

Who are the key executives at iBio Inc?

David Arkowitz is the director of iBio Inc. Other key executives at iBio Inc include Chief Legal Officer Marc Banjak , Interim CFO Felipe Duran , and Chief Scientific Officer Martin Brenner .

iBio Inc (IBIO) Insider Trades Summary

Over the past 18 months, David Arkowitz made no insider transaction in iBio Inc (IBIO). Other recent insider transactions involving iBio Inc (IBIO) include a net purchase of 24,835 shares made by Felipe Duran , a net purchase of 13,934 shares made by Marc Banjak , and a net purchase of 12,336 shares made by Martin Brenner .

In summary, during the past 3 months, insiders sold 0 shares of iBio Inc (IBIO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of iBio Inc (IBIO) were sold and 51,105 shares were bought by its insiders, resulting in a net purchase of 51,105 shares.

iBio Inc (IBIO)'s detailed insider trading history can be found in Insider Trading Tracker table.

iBio Inc Insider Transactions

No Available Data

David Arkowitz Mailing Address

Above is the net worth, insider trading, and ownership report for David Arkowitz. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, David Arkowitz's mailing address is: Burlington Ma 01803.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.